Abel Hall LLC
SPRY icon

Abel Hall LLC’s ARS Pharmaceuticals SPRY Stock Holding History

Abel Hall LLC’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-10,536
Closed -$84.4K – 1021
2026
Q2 		$84.4K Buy
+10,536
New +$90.6K 0.01% 855

Other funds holding SPRY

Pavaki Capital Management
Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return
Investment Management Associates
Investment Management Associates Greenwood Village, Colorado $490M AUM 6.7% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
American Assets Inc
American Assets Inc San Diego, California $310M AUM 4.36% 1-Year Est. Return
Norman Fields Gottscho Capital Management
Norman Fields Gottscho Capital Management New York $329M AUM 22.06% 1-Year Est. Return
Matisse Capital
Matisse Capital Portland, Oregon $256M AUM 15.28% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
USAdvisors Wealth Management
USAdvisors Wealth Management Eden Prairie, Minnesota $351M AUM 13.01% 1-Year Est. Return

Abel Hall LLC's SPRY Position: Q3 2026 in Review

Abel Hall LLC sold out of ARS Pharmaceuticals (SPRY) in Q3 2026, closing a stake of 10,536 shares — an estimated $84.4K sold.

Abel Hall LLC first reported a position in SPRY in Q2 2026 and held it in 1 quarter. The position peaked at $84.4K in Q2 2026. 33 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • Abel Hall LLC reported no remaining ARS Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Abel Hall LLC sold 10,536 ARS Pharmaceuticals shares in Q3 2026, an estimated $84.4K.
  • Abel Hall LLC first reported a position in ARS Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • Abel Hall LLC's ARS Pharmaceuticals position peaked at $84.4K in Q2 2026.
  • 33 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.